NCT01145807Unknown3 期
A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks
Celtic Pharma Development Services1 个研究点 分布在 1 个国家目标入组 738 人开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 738
- 试验地点
- 1
- 主要终点
- Cure Rate
研究概览
简要总结
The aim of this study is to establish the efficacy, clinical benefits, and safety of treatment with TDT 067 for clinically diagnosed distal subungual onychomycosis of the toenails caused by dermatophytes confirmed by positive mycology.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be between 18 and 75 years of age inclusive, of any race, and of either sex.
- •Female patients must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the Investigator.
- •Patients must have at least 1 great toenail (target toenail) with clinically diagnosed distal subungual onychomycosis involving between 25% and 65%, inclusive, of the nail and confirmed by KOH visualization and fungal culture positive for dermatophytes. (Patients with culture positive for dermatophytes alone or dermatophytes and non dermatophytes are eligible to participate.) If both great toenails meet inclusion criteria, the one with the greater involvement will be designated the target nail.
- •Patients must be able to understand the requirements of the study, abide by the restrictions, and return for all of the required examinations.
- •Patients must be willing to sign a statement of informed consent.
- •Patients must have a target great toenail with the capability to grow as determined by history of nail cutting.
- •Patients must be willing to refrain from using any nail polish products and other nail cosmetic products on any of the toenails and must be willing to refrain from professional pedicures for the duration of this study.
排除标准
- •Patients who have been treated with an investigational drug within 1 month prior to study start.
- •Patients who are pregnant or planning to become pregnant or who are lactating.
- •Patients with hypersensitivity to terbinafine or to any other ingredients of the formulation.
- •Patients who are unable to spray their toenails and the surrounding tissues on the affected foot without assistance.
- •Patients with symptomatic tinea pedis requiring treatment.
- •Patients using oral terbinafine within 6 months prior to the start of study; patients who have received other oral antifungals within 3 months.
- •Patients using topical antifungal treatments for onychomycosis within 1 month prior to the start of study; patients using topical antifungal treatments for the feet within 1 month prior to the start of the study.
- •Patients with any nail dystrophy that will interfere with the assessment of a clear nail. Patients who have toenail abnormalities or dystrophies that could prevent the restoration of a normal appearing nail in spite of a mycological cure for dermatophytes, including patients with psoriasis, lichen planus, malignancy or pigmentation disorders involving the nail unit, chemical damage, or onychodystrophy due to trauma or other structural deformities.
- •Patients with superficial white or proximal subungual onychomycosis.
- •Patients with a toenail infection involving a non dermatophyte alone.
- •Patients with involvement of the matrix (lunula) or the proximal 2 mm of nail as measured from the proximal nail fold.
- •Patients who have a nail plate with thickness greater than 2 mm or total thickness of the nail plus subungual debris measuring greater than 3 mm.
- •Patients with yellow streaks or dermatophytoma of the target toenail.
- •Patients with a history of peripheral arterial disease or diabetes mellitus.
- •Patients with any condition that in the opinion of the Investigator renders the patient unsuitable for participation in this study.
- •Patients with alanine aminotransferase (ALT) or aspartate (AST) levels greater than 2 times the upper limit of normal without clinical reason, unless, in the opinion of the Investigator, participation in this study would not place the patient at undue risk.
研究组 & 干预措施
Placebo
Placebo Comparator
non Transfersome® placebo
干预措施: Placebo (Drug)
Transfersome® vehicle
Sham Comparator
Transfersome® vehicle
干预措施: Transfersome (Drug)
TDT 067
Experimental
TDT 067
干预措施: TDT067 (Drug)
结局指标
主要结局
Cure Rate
时间窗: 52 Weeks
To compare complete cure rates for onychomycosis at Week 52 for TDT 067 versus non-Transfersome placebo. If the comparison between TDT 067 and non-Transfersome placebo is statistically significant in favor of TDT 067, the following additional primary efficacy objective: To compare onychomycosis cure rates at Week 52 for TDT 067 versus Transfersome vehicle
次要结局
- Cure Rate 48(48 Weeks)
- Cure Rate 52(52 Weeks)
- Cure Rate 60(60 Weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II Study of STA-2 in Patients With Chronic Stable AnginaChronic Stable AnginaNCT01484912Sinphar Pharmaceutical Co., Ltd79
已完成
2 期
Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat RhinoconjunctivitisAllergic RhinoconjunctivitisNCT00550875Laboratorios Leti, S.L.90
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT04289987CHA Vaccine Institute Co., Ltd.134
已完成
2 期
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction ProcedureSedationPainAnxietyNCT00894699Talphera, Inc40
已完成
2 期
A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in AdultsAllergic RhinitisNCT00604123Johnson & Johnson Pharmaceutical Research & Development, L.L.C.74